Home  »  Industry   »  Is Concert Pharmaceuticals Inc. (CNCE) a good stoc...

Is Concert Pharmaceuticals Inc. (CNCE) a good stock to buy now?

Concert Pharmaceuticals Inc. (NASDAQ: CNCE) is -65.82% lower on its value in year-to-date trading and has touched a low of $4.11 and a high of $13.50 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CNCE stock was last observed hovering at around $4.25 in the last trading session, with the day’s gains setting it 0.07% off its average median price target of $14.00 for the next 12 months. It is also 80.36% off the consensus price target high of $22.00 offered by 6 analysts, but current levels are 60.73% higher than the price target low of $11.00 for the same period.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Currently trading at $4.32, the stock is -6.49% and -23.36% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.42 million and changing 1.65% at the moment leaves the stock -53.70% off its SMA200. CNCE registered -58.78% loss for a year compared to 6-month loss of -63.11%. The firm has a 50-day simple moving average (SMA 50) of $5.1163 and a 200-day simple moving average (SMA200) of $9.0264.

The stock witnessed a -12.55% gain in the last 1 month and extending the period to 3 months gives it a -56.45%, and is 1.89% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.61% over the week and 6.67% over the month.

Concert Pharmaceuticals Inc. (CNCE) has around 71 employees, a market worth around $141.22M and $7.90M in sales. Distance from 52-week low is 5.11% and -68.00% from its 52-week high. The company has generated returns on investments over the last 12 months (-55.30%).

Concert Pharmaceuticals Inc. (CNCE) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Concert Pharmaceuticals Inc. (CNCE) is a “Buy”. 6 analysts offering their recommendations for the stock have an average rating of 1.80, where 0 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Concert Pharmaceuticals Inc. is expected to release its quarterly report on 08/10/2021 and quarterly earnings per share for the current quarter are estimated at -$0.69 with sales reaching $370k over the same period.The EPS is expected to grow by 27.20% this year, but quarterly earnings will post -66.20% year-over-year. Quarterly sales are estimated to grow 5,185.70% in year-over-year returns.

Concert Pharmaceuticals Inc. (CNCE) Top Institutional Holders

142 institutions hold shares in Concert Pharmaceuticals Inc. (CNCE), with 3.25M shares held by insiders accounting for 10.15% while institutional investors hold 84.07% of the company’s shares. The shares outstanding are 32.68M, and float is at 25.20M with Short Float at 4.52%. Institutions hold 75.53% of the Float.

The top institutional shareholder in the company is Blackrock Inc. with over 2.2 million shares valued at $27.86 million. The investor’s holdings represent 6.85% of the CNCE Shares outstanding. As of Dec 30, 2020, the second largest holder is Perceptive Advisors Llc with 2.15 million shares valued at $27.18 million to account for 6.68% of the shares outstanding. The other top investors are Bank of America Corporation which holds 1.88 million shares representing 5.83% and valued at over $23.73 million, while RA Capital Management, L.P. holds 5.67% of the shares totaling 1.82 million with a market value of $23.05 million.

Concert Pharmaceuticals Inc. (CNCE) Insider Activity

A total of 10 insider transactions have happened at Concert Pharmaceuticals Inc. (CNCE) in the last six months, with sales accounting for 5 and purchases happening 5 times. The most recent transaction is an insider sale by Tung Roger D, the company’s Chief Executive Officer. SEC filings show that Tung Roger D sold 13,480 shares of the company’s common stock on Feb 17 at a price of $7.20 per share for a total of $97056.0. Following the sale, the insider now owns 0.81 million shares.

Concert Pharmaceuticals Inc. disclosed in a document filed with the SEC on Feb 16 that Stuart Nancy (Chief Operating Officer) sold a total of 6,049 shares of the company’s common stock. The trade occurred on Feb 16 and was made at $7.32 per share for $44279.0. Following the transaction, the insider now directly holds 0.17 million shares of the CNCE stock.

Still, SEC filings show that on Feb 16, Munsie Jeffrey A (Chief Legal Officer) disposed off 3,763 shares at an average price of $7.32 for $27545.0. The insider now directly holds 46,153 shares of Concert Pharmaceuticals Inc. (CNCE).

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Concert Pharmaceuticals Inc. (CNCE): Who are the competitors?

The company’s main competitors (and peers) include Ionis Pharmaceuticals Inc. (IONS) that is trading -23.85% down over the past 12 months. Jazz Pharmaceuticals plc (JAZZ) is 46.96% up on the 1-year trading charts. Short interest in the company’s stock has fallen -69.41% from the last report on Apr 14, 2021 to stand at a total of 1.14 million short shares sold with a short interest ratio of 2.85.

Related Posts




Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam